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EVIDENCE BASED NEURO-ONCOLOGY
Role of surgery in multifocal glioblastoma
Syeda Kubra Kishwar Jafri, Syed Sarmad Bukhari, Muhammad Shahzad Shamim

Abstract
The management of multifocal glioblastomas is a point of
constant discussion amongst neuro-oncologists. Best
outcomes in glioblastoma management come from gross
total resection (GTR) followed by concomitant radiation
and chemotherapy (CCRT). Multifocal disease is resistant to
GTR. Conventional management of these lesion is usually
biopsy only followed by CCRT. Recent evidence has shown
that there may be some benefit to attempting GTR of the
largest lesion whenever safe to do so.
Keywords: Glioblastoma multiforme; multifocal;
radiotherapy; chemotherapy
DOI: https://doi.org/10.47391/JPMA.22-021

Introduction
Multifocal glioblastoma (mGBM), formerly considered
uncommon, is an increasingly diagnosed subgroup of the
most common malignant primary brain tumour, the
glioblastoma (GBM).1 The standard management of
multifocal GBM is still under debate. Surgical or stereotactic
biopsy has been recommended for diagnostic
authentication but the benefit of surgical debulking is yet
to be established in the definitive management of
multifocal glioblastoma.2
Review of literature
Multifocal glioblastoma account for around 20% of all
GBMs.1-5 By definition, glioblastomas are termed multifocal
when multiple distinct foci of tumour enhancement are
encountered demonstrating microscopic connections or a
clear parenchymal dissemination route on fluid-attenuated
inversion recovery (FLAIR) sequences of Magnetic
Resonance Imaging, which is additionally the basis of their
diﬀerentiation from metastatic disease as well as the less
commonly
encountered
subgroup,
multicentric
glioblastoma (Figure).1,5,6
Multiple lesions of mGBM can occur either synchronously
or metachronously and maybe connected via white matter
tracts, gray matter, neurons, blood vessels, meninges,
cerebrospinal fluid or the ventricular systems and
dissemination widely occurs via the meningealsubarachnoid space.1,7 These are more common in the
supratentorial region though a combined supra and
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Figure:

A) MRI Brain with contrast axial sections demonstrating a multifocal
glioblastoma. B) FAIR image demonstrating FLAIR hyperintensities
connecting the individual lesions.

infratentorial involvement has also been observed.2
Presentation may range from signs and symptoms of raised
intracranial pressure to sensory-motor deficits and
generalized tonic-clonic seizures.2 The prognosis is
considered to be generally poor for mGBM with a median
survival of 7.6 to 12 months.1,4,8 Surgical resection followed
by chemotherapy and radiotherapy is the standard of care
for solitary GBM but no such standard treatment guidelines
have been established for mGBM.1,5,8,9 Resection vs the
conventionally popular biopsy-only approach for mGBM
has been a subject of debate for decades.
Earlier evidence is in support of the biopsy-only custom,
however, current data hugely favours craniotomy followed
by surgical resection/debulking, particularly in patients
with preserved performance status.3-5,7,9 This is ascribable
to increased overall survival in patients undergoing
resection (16.3 months) rather than biopsy alone (7
months).5,9 An exception to this was a single-center
retrospective study,7 where the median survival for patients
undergoing resection vs biopsy was equivalent (8.4 vs 7.5
months), though these results were described for multiple
glioblastomas as a whole, with no distinction between
multifocal or multicentric disease.7 Extent of surgical
resection (EOR) is validated to be directly related to
improved overall survival.3-5,9 A resection of greater than
27.7% of the initial tumour volume was also found to
positively influence the survival probability and increase 6month survival, but the analysis was a univariate.4
Current evidence is firmly in favour of achieving maximum
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safe resection for glioblastomas, whenever possible
without functional compromise therefore, gross total
resection (GTR) is exceedingly recommended, particularly
in easily accessible tumours that are predicted to have a
moderate functional impairment, with subtotal resection
(STR) reserved for less accessible tumours or those
involving functional brain areas.1,3,4 Haque et al., in the
largest study to date, based on US National Cancer
Database, described the median overall survival of 11.5
months, 9 months, and 5.8 months for gross total resection
(GTR), subtotal resection (STR) and biopsy alone strategies,
respectively, while a median overall survival of 17 months
following GTR, was reported from a retrospective analysis
of 100 patients.3,5
Several diﬀerent thresholds for the extent of resection
(EOR) of GBMs have been described throughout literature,
each pledging survival benefit. Di et al., established the
cutoﬀ for EOR of the dominant contrast-enhancing lesion
in mGBMs at 85% using receiver operating characteristic
curve and identified >85% EOR to be tied to superior
overall survival (22.4 months vs 8.4 months for <85% EOR),
though progression-free survival did not significantly diﬀer
with greater than or less than 85% resection.9 Li et al.,
further concluded that complete removal of T1 contrastenhancing lesion along with resection of a significant area
of FLAIR hyperintensity was significantly profitable, without
diminishing postoperative outcomes.1
Though most of the previously described studies were
based on resection of a single or usually two lesions,
Hasneen et al., found aggressive resection (100% EOR) of
all lesions in an mGBM via multiple craniotomies in a single
session, to increase survival with no rise in postoperative
morbidity and the results were comparable to surgical
resection in patients with unifocal GBMs.10 These are
however, account for a small subset of patients in clinical
practice.
In an eﬀort to make maximum safe resection possible,
GBMs can be divided into two categories, the proliferation
dominant and the diﬀusion dominant, based on the ratio
of T1 weighted contrast-enhancing area and FLAIR
hyperintense region. For proliferation dominant lesions, it
is advised to extend resection up to the FLAIR hyperintense
area, while the diﬀusion dominant lesions require a less
aggressive approach.1 Still further, fluorescence technology
involving the use of fluorescent protoporphyrin IX (PPIX), a
derivative of 5-aminolevulinic acid (5-ALA) and fluorescein
sodium may help to ascertain tumour boundaries and the
extent of resection, particularly in tumours involving
functional regions, whereas for non-functional regions,
FLAIR hyperintense signals should be employed to
determine resection boundaries.1
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Nevertheless, it is vital to consider further elements that
add to and impact the decision for aggressive surgical
resection. These chiefly include age, Karnofsky
performance scale (KPS), location, distribution and number
of lesions, and the probability of receiving adjuvants.1,5,7
Advanced age and a low KPS (<70) have both proved to be
poor prognostic factors.5 The involvement of key structures,
functional areas, subcortical areas, the spread to
contralateral hemisphere and deeper invasion are also
known to imply poor survival, while adjuvant therapies,
whenever possible and accessible warrant improved
survival.4,5 Though the greater number of lesions may
indicate worse survival, as was concluded by a
retrospective study on multiple glioblastomas, to directly
relate multiplicity with a guarded prognosis is appearing
to be a simplistic approach to determining patient
outcomes.1,6,8
Accordingly, several studies have described models in
consideration of these parameters. In their retrospective
analysis, Friso et al., having adjusted their data for age, KPS,
number of lesions, and adjuvant therapy, deduced GTR,
STR, and partial resection, to be associated with better
overall survival, whereas progression-free survival was
linked to GTR only.5 An exploratory study further signified
improved overall survival following resection vs. biopsy, in
their model adjusted for age, preoperative tumour burden,
and mutation markers.9 Furthermore, cytoreductive
surgery oﬀers the added advantage of alleviating
symptoms by relieving mass eﬀect, reducing intracranial
pressure, generating local immune responses, reducing
hypoxia by tumour cells, and promoting penetration of
chemotherapeutic agents, which augments the eﬃcacy of
adjuvant treatments.5,9

Conclusion
Literature suggests that surgical debulking oﬀers a survival
benefit and should be attempted whenever possible in the
treatment of multifocal glioblastoma. However, care should
be taken to consider other factors responsible for
influencing the outcome of these patients including new
postoperative deficits.
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